-
Abstract Number: PB2486
E-selectin Inhibitor Is Superior to LMWH for Treatment of Experimental Venous Thrombosis
-
Abstract Number: PB0152
Early Indicators of Thromboembolic Events Caused by Prolonged Tourniquet Application: A Rat Model
-
Abstract Number: PB2437
Early Physiotherapy Intervention Reduces the Long Term Effects of Venous Thromboembolism and Promotes an Improved Quality of Life: Results from a Pilot Study
-
Abstract Number: PB2536
Early Plasma Transfusion and Maternal Outcomes in Women with Persistent Postpartum Haemorrhage: Does the Amount of Resuscitation Fluids Matter?
-
Abstract Number: PB1170
Economic Burden Associated with Vaso-Occlusive Crisis Management in Patients with Sickle Cell Disease
-
Abstract Number: PB2407
Edoxaban for the Long-Term Therapy of Venous Thromboembolism in Real-Life RIETE Registry
-
Abstract Number: PB2409
Edoxaban Treatment of Venous Thromboembolism in Routine Clinical Practice in the Non-Interventional Global ETNA-VTE Program: A Sub-Analysis by Age Groups
-
Abstract Number: PB0554
Effect of Activated Charcoal in Removing Interference in Thrombophilia Assays: Resistance to Activated Protein C, Activity of Coagulation Factor VIII and Antithrombin Activity
-
Abstract Number: PB0549
Effect of Antiepileptic Therapy on Platelet Aggregation
-
Abstract Number: PB2395
Effect of Antiplatelet Therapy on Clinical Outcome of Patients Treated with Anticoagulation for Acute Venous Thromboembolism
-
Abstract Number: PB0762
Effect of B-Mode Ultrasound-Guided Pulsed – High Intensity Focused Ultrasound-Mediated Inertial Cavitation Thrombolytic Therapy Accompanied by Air-Contained Sonicated Dextrose Albumin Microbubbles Administration on Embolic Artery Occlusion
-
Abstract Number: PB0044
Effect of BTK Inhibition on Platelet-mediated Inflammation in an Obese Rhesus Macaque Model of Early Atherosclerosis
-
Abstract Number: PB1819
Effect of cART on Platelet:Lymphocyte Ratio in HIV Patients Initiating Treatment
-
Abstract Number: PB0510
Effect of Dabigatran versus Enoxaparin on Blood Coagulation using the Viscoelastic Coagulation Test
-
Abstract Number: PB1221
Effect of Foot Bath on the Plasma Concentration of Plasminogen Activator Inhibitor-1 Produced by Endothelial Cells in Healthy Subjects
-
Abstract Number: PB1839
Effect of Human Myeloperoxidase on Ca2+-response, Membrane Conductivity and Phosphatidylserine Exposure on Platelet Surface
-
Abstract Number: PB1897
Effect of Immune-Purified aβ2-Glycoprotein I (aβ2GPI) and Anti Phosphatidylserine/Prothrombin (aPS/PT) Antibodies on Thrombin Generation
-
Abstract Number: PB0217
Effect of Mg(II) Ion on the Interaction of Coagulation Factors with Phospholipid Membranes
-
Abstract Number: PB1113
Effect of Oral Anticoagulant Use on Surgical Delay and Outcomes in Hip Fracture Patients: A Systematic Review and Meta-Analysis
-
Abstract Number: PB2054
Effect of Patient and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) Study
-
Abstract Number: PB0025
Effect of Phosphomimetic Endothelial Nitric Oxide Synthase – Loaded Microbubbles-Mediated Transfection Therapy using B-Mode Ultrasound-Guided Focused – Low Level Confocal Dual-Pulse Electrohydraulic Shock Waves on Early Stage Atherosclerosis
-
Abstract Number: PB0045
Effect of Photobiomodulation Therapy on Arterial Biomechanical Parameters in a Rabbit Carotid Artery Model of Early Stage Atherosclerosis
-
Abstract Number: PB0046
Effect of Photodynamic Therapy on Arterial Biomechanical Parameters in a Rabbit Carotid Artery Model of Neointimal Hyperplasia
-
Abstract Number: PB0097
Effect of Pulsatility on Thrombosis Modelling in Cerebral Aneurysms
-
Abstract Number: PB1116
Effect of rFVIIa on Thromboelastogram Parameters in Haemophilia A Patients with Inhibitor
-
Abstract Number: PB0763
Effect of Streptokinase-Loaded Microbubbles-Mediated B-Mode Ultrasound-Guided Sono-Photomechanic Combination Thrombolytic Therapy on Atherothrombotic Stenosis
-
Abstract Number: PB1430
Effect of Synthetic Inhibitors on HIT Antigenic Complex – Therapeutic Approach Alternative to Anticoagulation
-
Abstract Number: PB0807
Effect of the First Factor VIII Infusions on Immunological Biomarkers in Children with Hemophilia A: Results from the HEMFIL Study
-
Abstract Number: PB1636
Effect of Three Types of Mixed Anesthesia (MMB) for Platelet Function
-
Abstract Number: PB0581
Effect of Vitamin K Antagonist Therapy on the Dynamics of Hypercoagulation Syndrome in Patients with Deep Vein Thrombosis
-
Abstract Number: PB0351
Effect of Warfarin Addition in Diabetic Foot Ulcer Patients Receiving Cilostazol In Mohammad Hoesin Hospital, South Sumatera, Indonesia
-
Abstract Number: PB2412
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in a Large Daily Practice Cohort
-
Abstract Number: PB2166
Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Ph-negative Myeloproliferative Neoplasms and Venous Thromboembolism
-
Abstract Number: PB2113
Effectiveness and Safety of Enoxaparin in Patients with Active Cancer and Venous Thromboembolism (VTE): A Systematic Literature Review
-
Abstract Number: PB1310
Effectiveness and Safety of Primary Thromboprophylaxis in Pediatric Renal Transplant: a Systematic Review of the Literature and Meta-Analysis
-
Abstract Number: PB2211
Effectiveness and Safety of Pulmonary Rehabilitation to Reduce Functional Impairment Based on the Post-PE Syndrome
-
Abstract Number: PB2171
Effectiveness and Safety of Rivaroxaban in Patients with Cancer-associated Venous Thromboembolism
-
Abstract Number: PB1226
Effectiveness of a Self-management Program in the Treatment Control of Oral Anticoagulants Antivitamin K
-
Abstract Number: PB2382
Effectiveness of Implementing a Prophylaxis Protocol for Thromboembolic Events in Patients Admitted to a Tertiary Hospital
-
Abstract Number: PB2384
Effectiveness of Thromboprophylaxis in the Prevention of Peripherally Inserted Central Catheter (PICC) Associated Venous Thromboembolism in Pediatric Patients: A Case-control Study
-
Abstract Number: PB0669
Effects of Anticoagulants and Common Interfering Substances on Four Commercially Available dRVVT Assays
-
Abstract Number: PB0181
Effects of Anticoagulants on Fibrin Clot Structure: A Comparison between Vitamin K Antagonists and FXa inhibitors
-
Abstract Number: PB2200
Effects of Body Mass Index on the Human Plasma Proteome – Potential Drivers of Obesity-related Cardiovascular Disease?
-
Abstract Number: PB0371
Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Advanced Colorectal Cancer Patients
-
Abstract Number: PB1660
Effects of GPVI on Clot Structure: Reduction in Procoagulant Platelets in GPVI-Deficient Clots
-
Abstract Number: PB0150
Effects of Hibernation on the Platelet Proteome of 13-lined Ground Squirrels
-
Abstract Number: PB0716
Effects of Lysine-Containing Peptides Treatment on FXIII Activity and Fibrinogen Level of Metabolic Disorders
-
Abstract Number: PB0254
Effects of Plasmin on Factor XII Structure and Activation
-
Abstract Number: PB0572
Effects of Rivaroxaban on Thrombophilia Screening Tests – Results from a UK NEQAS (Blood Coagulation) Exercise
-
Abstract Number: PB0707
Effects of Squalene-Adenosine Nanoparticles on Platelet Aggregation, Thrombin Generation and Endothelial Cells
-
Abstract Number: PB1817
Effects of the Bacterial Toxin Cytotoxic Necrotising Factor 1 on Platelet Function
-
Abstract Number: PB0930
Efficacy and Safety of a 21-Day Individualized Dosing Interval in Patients with Hemophilia B Treated with rIX-FP
-
Abstract Number: PB0876
Efficacy and Safety of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients with Severe or Moderately Severe Hemophilia A: Results from a Phase 4 Study
-
Abstract Number: PB2378
Efficacy and Safety of Apixaban for the Primary Prevention of VTE among Patients with Gastrointestinal Cancers: A Post-hoc Analysis of the AVERT Trial
-
Abstract Number: PB0916
Efficacy and Safety of BAY 94-9027 Prophylaxis for ≥5 Years: Outcomes in 36 Patients from the PROTECT VIII Extension Study
-
Abstract Number: PB0302
Efficacy and Safety of Ciraparantag in Reversing Apixaban and Rivaroxaban as Measured by Whole Blood Clotting Time in Healthy Adults
-
Abstract Number: OC 12.1
Efficacy and Safety of Dabigatran Etexilate for Treatment of Venous Thromboembolism in Paediatric Patients Aged from Birth to < 2 Years - Results of the DIVERSITY Trial
-
Abstract Number: PB1176
Efficacy and Safety of Fibrinogen Concentrate for On-Demand Treatment of Acute Bleeding and Surgical Prophylaxis in Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-04 Study
-
Abstract Number: PB2520
Efficacy and Safety of Low-Molecular-Weight Heparin for the Prevention of Pregnancy-Related Recurrent Venous Thromboembolism and Obstetrical Complications
-
Abstract Number: PB2361
Efficacy and Safety of Pre-Operative Insertion of Inferior Vena Cava Filter in Patients Undergoing Bariatric Surgery: A Systematic Review
-
Abstract Number: PB0155
Efficacy and Safety of Prothrombin Complex Concentrate in Obstetric Hemorrhage
-
Abstract Number: PB1336
Efficacy and Safety of Romiplostim in Children with Chronic and Persistent Immune Thrombocytopenic Purpura
-
Abstract Number: PB2247
Efficacy and Safety Profile of Direct Oral Anticoagulants in Consecutive Patients with Severe Hereditary Thrombophilia: A Single-centre Cohort Study
-
Abstract Number: PB0921
Efficacy and Target Joint Resolution with Pharmacokinetic-Guided Rurioctocog Alfa Pegol Prophylaxis Targeting Two Factor VIII trough Levels in Patients with Severe Hemophilia A: Post-Hoc Analysis of the Phase 3 PROPEL Trial
-
Abstract Number: PB1392
Efficacy of Antiplatelet Therapy in Patients with Acute Ischemic Stroke Treated with Acetylsalicylic Acid
-
Abstract Number: PB1500
Efficacy of Novoseven in the Treatment of Bleeding Episodes During Glanzmann´s Thrombasthenia
-
Abstract Number: PB1023
Efficacy of Platelet-rich Plasma in the Treatment of Hemophilic Arthropathy
-
Abstract Number: PB1877
Efficacy of Preemptive Subcutaneous Rituximab in Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Study of 12 Cases
-
Abstract Number: PB2095
Efficacy of Primary Thromboprophylaxis Agents (PTA) in Multiple Myeloma (MM) Treated with Immunomodulators (IMiD): A Network Meta-Analysis
-
Abstract Number: PB2458
Efficacy of Reversible Factor Xa Inhibitors is Related to the Level of Factor VIII: Best Practice is Adjustment of the Dose for Factor VIII Level?
-
Abstract Number: PB2527
Efficiency of Inhibition of Thrombin Generation and Stimulation of Fibrinolysis in vitro Fertilization Programs
-
Abstract Number: PB0730
Eight Succesfull Pregnancies in Patients with Congenital Fibrinogen Disorders – Single Centre Study
-
Abstract Number: PB0914
Elbow Embolization for Recurrent Massive Hemarthrosis: A Case Series with Successful Outcome
-
Abstract Number: PB1222
Elderly Patients with Atrial Fibrillation Have Higher Risk of Geriatric Syndromes: Results of the Nursing Study
-
Abstract Number: PB1322
Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating Let-7b in Immune thrombocytopenia
-
Abstract Number: PB/LB01
Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating let-7b in Immune Thrombocytopenia
-
Abstract Number: PB/CO19
Elevated D-dimers Useful Prediction of Pulmonary Artery Thrombosis in COVID-19 Patients at Initial Presentation to Hospital
-
Abstract Number: PB0114
Elevated Levels of Activated Factor XII Are Associated with an Increased Risk of Atherothrombotic Events in Peripheral Artery Disease
-
Abstract Number: PB0771
Elevated Levels of Circulating Markers of Neutrophil Extracellular Traps (NETs) Are Associated with Unfavorable Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis
-
Abstract Number: PB2138
Elevated Plasma Factor VIII Levels Are Associated with Hypercoagulability and Shorter Survival in Patients with Non-Hodgkin Lymphoma
-
Abstract Number: PB1971
Elevated Plasminogen Activator Inhibitor Type-1 and Soluble Thrombomodulin of Type 2 Diabetes Mellitus Subjects with Increasing Loss of Glycemic Control in Calabar, Southern Nigeria
-
Abstract Number: PB2108
Elevated Von Willebrand Factor Antigen and Activity Levels Are Risk Factors for Predicting Thrombosis in Cancer
-
Abstract Number: PB2264
Elevated von Willebrand Factor Antigen Levels and Ristocetin Cofactor Activity are Risk Factors in Predicting Deep Vein Thrombosis
-
Abstract Number: PB0847
ELISA-based Quantification of intracellular FVIII Protein in IPS Derived Vascular Endothelial Cells from HA-patients with Nonsense Mutations
-
Abstract Number: PB1341
Eltrombopag Suppresses Excessive Inflammation in Hepatitis B-Related Immunologic Thrombocytopenia through Inhibition of Toll-Like Receptor 4 Signaling Pathway
-
Abstract Number: PB1355
Eltrombopag Therapy in Pediatric Acute and Chronic Immune Thrombocytopenia
-
Abstract Number: PB2068
Emergency Room Access of Patients on DOACs: A Six Years Single Center Experience
-
Abstract Number: PB1652
Emerging Roles of CLEC-2 during Development of Monocrotaline-Induced Liver Injury in Mice
-
Abstract Number: PB0977
Emicizumab and Surgery in Severe Haemophilia A with Inhibitor: Our First Experience
-
Abstract Number: PB1164
Emicizumab beyond Annualized Bleeding Rate: Do Laboratory Assays Help Predict Emicizumab Effects?
-
Abstract Number: PB1165
Emicizumab beyond Annualized Bleeding Rate: How Does Emicizumab Affect Bone Biomarkers?
-
Abstract Number: PB0915
Emicizumab Concentration in Children: A Single Centre Real World Experience
-
Abstract Number: PB0784
Emicizumab for the Treatment of Acquired Hemophilia A
-
Abstract Number: PB1141
Emicizumab in the Management of Hemophilia A: Real World Experience in East Malaysia
-
Abstract Number: PB0822
Emicizumab Prophylactic Therapy in Patients with Hemophilia A Is Better Measured by Thrombin Generation Assay Than Thromboelastography
-
Abstract Number: PB1081
Emicizumab Prophylaxis in a Racially Diverse Pediatric Population with Hemophilia A with and without Inhibitors
-
Abstract Number: PB0323
Emicizumab Treatment in Pediatric Patients with Hemophilia A without Inhibitors: A Single-Institution Study
-
Abstract Number: PB1161
Emicizumab, beyond Annualized Bleeding Rates: Real World Joint Health and Physical Activity Data
-
Abstract Number: PB2427
EmpoderACO: Elaboration and Validation of a Protocol for Behavioral Change in Patients on Warfarin
-
Abstract Number: PB2125
Empowering Cancer Patients for Non-Pharmacological Primary Prevention and Early Recognition of Cancer-Associated Thrombosis (CAT): The EMPATIC-CP Survey
-
Abstract Number: PB0178
Endocytosis of Factor VIII by Human Dendritic Cells in the Presence of Anti-Factor VIII Antibodies from Patients with Hemophilia A
-
Abstract Number: PB0076
Endogenous PCSK9 Is Related to Circulating CD34bright/CD146– Cells in Patients with Type 2 Diabetes Mellitus
-
Abstract Number: PB1982
Endothelial Protein C Receptor Signaling via Protease-activated Receptor 1 Promotes Neovascularization after Ischemia in Mice
-
Abstract Number: PB0866
Endothelial Specific Isoform of Type XVIII Collagen (COL-18N): A Marker of Vascular Integrity in Hemophilic Arthropathy
-
Abstract Number: PB1127
Endovascular Abdominal Aortic Aneurysm Repair in a Mild Haemophilia A Patient: A Case Report
-
Abstract Number: PB2212
Endovascular Management with Iliofemoral Stenting in a Patient with Chronic Venous Occlusive Disease and Antiphospholipid Antibodies
-
Abstract Number: PB0490
Enhancing Transfusable Platelets Using mRNA Therapy to Produce Exogenous Proteins
-
Abstract Number: PB2307
Epidemiologic Study of Patients with Thrombotic Events Referred to Tertiary Hospital in Southern Iran
-
Abstract Number: PB2250
Epidemiology and Clinicopathology of Latent versus Active JAK2-Myeloproliferative Neoplasms (MPN) in Splanchnic Venous Thrombosis
-
Abstract Number: PB2347
Epidemiology and Risk Factors for Thrombosis in Pregnancy and Puerperium. Experience in One Reference Center in Mexico
-
Abstract Number: PB1980
Epigenetic Regulation of Endothelial Dysfunction in Venous Thromboembolism
-
Abstract Number: PB1629
Epinephrine Enhances Platelet Aggregation at the Expense of Procoagulant Activity
-
Abstract Number: PB1603
Essential Thrombocythemia (ET): A Study of Clinical Features and Treatment Outcome in Pediatric Patients at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
-
Abstract Number: PB2257
Essential Thrombocythemia Complicated with Portal Vein Thrombosis and Liver Cirrhosis – A Case Report
-
Abstract Number: PB0538
Establishing an External Quality Assessment Scheme (EQAS) for D-Dimer Assay in India: Results from a Pilot
-
Abstract Number: PB1574
Establishing Reference Intervals for von Willebrand Factor Multimers
-
Abstract Number: PB0646
Establishing Reference Range and Validating Precision Performance of the TES-6s System
-
Abstract Number: PB0514
Establishment of a Novel Mixing Test Using Activated Partial Thromboplastin Time (aPTT)-Based Clot Waveform Analysis
-
Abstract Number: PB0682
Establishment of Reference Intervals for Automated Light Transmission Aggregometry
-
Abstract Number: PB0521
Estimation and Analysis of Measurement Uncertainty Acceptability: The Interest of Bayesian Inference
-
Abstract Number: PB2434
ETNA VTE Europe: A Contemporary Snapshot of VTE Patients Treated with Edoxaban in Clinical Practice across Eight European Countries
-
Abstract Number: PB2432
ETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban
-
Abstract Number: PB2478
ETNA-VTE Global: Evaluation of Bleeding Risk Based on VTE-BLEED Score on 12-month Outcomes in a Population Treated with Edoxaban
-
Abstract Number: PB1424
Evaluation of 4T Probability Scores, Heparin PF4 Antibody, and Serotonin Release Values in End Stage Renal Disease Patients in the Assessment of Heparin Induced Thrombocytopenia
-
Abstract Number: PB1679
Evaluation of a New Agonist (ADP-HS®) for Platelet Function Testing with Light Transmittance Aggregometry: A Bi-Center Study
-
Abstract Number: PB0577
Evaluation of a New Benzylsulfonyl-D-Arg-Pro-4-Amidinobenzylamide (BAPA) Blood Collection Tube for Platelet Function Studies
-
Abstract Number: PB0665
Evaluation of a New Device to Remove Direct Oral Anticoagulants (DOACs) from Plasma Samples
-
Abstract Number: PB1888
Evaluation of a Rapid, Automated Chemiluminescent ADAMTS-13 Activity Assay for the ACL AcuStar
-
Abstract Number: PB1850
Evaluation of Analyser Flag ´Abnormal Platelet Distribution´ in Routine Complete Blood Count (CBC)
-
Abstract Number: PB0080
Evaluation of Biological Effects of Airborne / Urban Pollution Particles
-
Abstract Number: PB0911
Evaluation of Bleeding in Haemophilia Carriers by ISTH-BAT: A Single Center Experience
-
Abstract Number: PB1565
Evaluation of Carriers of Type 3 von Willebrand Disease with PFA200
-
Abstract Number: PB0341
Evaluation of Coagulation FIX Binding to Collagen IV and the Impact on Thrombin Generation
-
Abstract Number: PB1398
Evaluation of Dual Antiplatelet Therapy Combining Aspirin and Clopidogrel for Intracranial Stenting Procedures: A Retrospective Single Center Study
-
Abstract Number: PB0597
Evaluation of EQA Material on Lumira Dx Point of Care Platform: UK NEQAS for Blood Coagulation Study
-
Abstract Number: PB0908
Evaluation of Factors Associated with Extended Half-Life Product Utilization for Men with Hemophilia B Participating in the Community Counts Registry from 2014-2018
-
Abstract Number: PB0967
Evaluation of Factors Associated with Prophylaxis Treatment Regimen among Men with Hemophilia B Participating in the Community Counts Registry from 2014-2018
-
Abstract Number: PB1409
Evaluation of Fondaparinux (Arixtra®) at a Large Academic Medical Center
-
Abstract Number: PB0433
Evaluation of Global Coagulation Assays in Pregnancy
-
Abstract Number: PB0628
Evaluation of Hemostatic Markers in Patients with Sickle Cell Disease Using or Not Hydroxyurea
-
Abstract Number: PB0631
Evaluation of IgG4 ELISA for the Screening of Factor VIII Inhibitors in Hemophilia A
-
Abstract Number: PB1066
Evaluation of Inhibitor Risk Prediction Tools Based on Genetic Risk Factors in Persons with Hemophilia A
-
Abstract Number: PB0620
Evaluation of INR and APTTs Using the Q Family of Analysers in Comparison to ACL TOP
-
Abstract Number: PB0841
Evaluation of Intron 22 and Intron 1 Inversions of Factor VIII Gene in Haemophilia A Patients
-
Abstract Number: PB0447
Evaluation of Plasma Level of Soluble CLEC2, a Novel Platelet Activation Marker, in Patients with Sepsis Induced Coagulopathy -A Pilot Study
-
Abstract Number: PB1628
Evaluation of Platelet Count and Platelet Indices of Male Cannabis Sativa (Marijuana) Consumers in Calabar South, Cross River State, Nigeria
-
Abstract Number: PB2221
Evaluation of Platelet Indices in Patients with Splanchnic Vein Thrombosis
-
Abstract Number: PB1403
Evaluation of Platelet Reactivity in Pediatric Patient on Dual Antiplatelet Therapy after Stent Implantation of Ductus Arteriosus: A Case Report
-
Abstract Number: OC 11.4
Evaluation of Platelets Activation and Fibrin Clotting in Post-Menopausal Women with Takotsubo Syndrome
-
Abstract Number: PB0335
Evaluation of Structurally Altered Protein in Factor VIII Therapeutic Products Using Chromatography on Immobilized von Willebrand Factor
-
Abstract Number: PB0449
Evaluation of the Accuracy of INR Values Measured by a POCT System in a German Clinic with Patients Taking Phenprocoumon as VKA Therapy
-
Abstract Number: PB0657
Evaluation of the Atellica® COAG 360 (Siemens Healthineers) at Caen-Normandy University Hospital (FRANCE)
-
Abstract Number: PB0172
Evaluation of the CEPHEN Reagent for the Determination of Activated Partial Thromboplastin Time in Current Practice
-
Abstract Number: PB0342
Evaluation of the Effect Emicizumab Neutralizing Antibodies on aPTT Clotting-based Tests Results in Patients Treated with Emicizumab
-
Abstract Number: PB0516
Evaluation of the Newly-developed Collagen Induced Platelet Aggregation Level (CPAL) System in Aggregometer on Automated Coagulation Analyzer
-
Abstract Number: PB1175
Evaluation of the Potential Utility of the Total Thrombus-Formation Analysis System (T-TAS) in Comparison to the Platelet Function Analyzer (PFA) in Subjects with Primary Hemostatic Defects
-
Abstract Number: PB0037
Evaluation of the Selectivity of BCR-ABL Tyrosine Kinase Inhibitors (TKIs): A Systematic Review
-
Abstract Number: PB1213
Evaluation of the Skeletal Lesions in the Lebanese Patients with Afibrinogenemia
-
Abstract Number: PB0627
Evaluation of the Succeeder SF-8200 Fully Automated Coagulation Analyzer
-
Abstract Number: PB2428
Evaluation of Thrombin and Fibrin Generation in Venous Thromboembolism (VTE) Patients Receiving Anticoagulation
-
Abstract Number: PB1375
Evaluation of Thrombocytopenia and Fetomaternal Outcome in Pregnancy at a Tertiary Care Hospital
-
Abstract Number: PB0640
Evaluation of Thrombogenicity of Apheresis-collected Platelet Concentrates under Blood Flow Condition
-
Abstract Number: PB0476
Evaluation of Thrombomodulin Levels in Women with Breast Cancer Undergoing Doxorubicin Treatment
-
Abstract Number: PB0255
Evolutionary History of the Kallikrein-Kinin System and Factor XI
-
Abstract Number: PB0817
Examining the Hemophilia Disability Paradox
-
Abstract Number: PB1526
Excessive Angiogenesis in von Willebrand Factor Knockout Mice is Accompanied by Increased Perivascular Coverage of Neovessels
-
Abstract Number: PB0611
Excluding Anticoagulants and Antiplatelet Drugs with Rotational Thromboelastometry
-
Abstract Number: PB1627
Exercise Training Enhances Mitochondrial Bioenergetics of Platelets in Patients with Peripheral Arterial Disease
-
Abstract Number: OC 05.4
Exogenous Microparticles Bearing Tissue Factor Improve Outcome After Collagenase-Induced Intracranial Hemorrhage
-
Abstract Number: PB0500
Exome-array Analysis of Plasma Hemostatic Factors D-dimer, tPA and PAI-1 Identifies Novel Genes
-
Abstract Number: PB1293
Expanding the Spectrum of Heterozygous Antithrombin Deficiency Type II HBS? Unusual Presentation of Thromboembolic Events in Two Children
-
Abstract Number: PB1099
Expectations and Concerns of Patients with Haemophilia towards Gene Therapy – Results of Patients and Expert Focus Groups
-
Abstract Number: PB0790
Experience with Recombinant Porcine FVIII in Patients with Acquired Factor VIII Deficiency Undergoing Major Surgery
-
Abstract Number: PB1527
Explanations for Rise of Levels of Factor VIII and von Willebrand Factor Antigen with Age
-
Abstract Number: PB1861
Exploration of Coagulation Disorders, von Willebrand Factor and ADAMTS13 in a Cohort of 45 Patients with Hemophagocytic Lymphohistiocytosis
-
Abstract Number: PB2201
Exploring Alternative Approaches of Using the Villalta Scale to Capture the Post-Thrombotic Syndrome: A Sub-analysis of the ATTRACT Trial
-
Abstract Number: PB1105
Exploring RNA Editing System as Innovative Correction Strategy for Hemophilia A
-
Abstract Number: PB0404
Exploring the Effectiveness of DNA and Glycosaminoglycans as Inhibitors of Histones
-
Abstract Number: PB0813
Exploring the Relationship between Common Complications of Haemophilia and Anxiety and Depression in People with Haemophilia A
-
Abstract Number: PB0804
Exploring the Relationship between Condition Severity and Health-Related Quality of Life in Haemophilia A
-
Abstract Number: PB0375
Expression of Circulating Microparticles Procoagulant Activity in Cirrhotic Patients
-
Abstract Number: PB1956
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes
-
Abstract Number: PB1132
Extended Half-life FIX and Disruptive Therapies in Carriers with FVIII and FIX Deficiencies: Preliminary Experience
-
Abstract Number: PB0890
Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Previous Treated Hemophilia A Patients
-
Abstract Number: PB2455
Extended Treatment in Unprovoked Venous Thromboembolism: What Is Important to Patients?
-
Abstract Number: PB0453
Extensive Characterization of the Hemostatic Changes during Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Carcinomatosis
-
Abstract Number: PB0533
Extensive Experiments in (Un)Diagnosed Bleeding Patients with Prolonged Platelet Function Analyser Closure Times
-
Abstract Number: PB0274
External Quality Assurance (EQA) for the Thromboelastometry Devices: UK NEQAS BC Programme Update
ISTH 2020 Congress
July 12-14, 2020. Virtual Congress.